Landscape Capital Management L.L.C. Has $2.80 Million Stock Position in Axsome Therapeutics, Inc. $AXSM

Landscape Capital Management L.L.C. lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 20.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 15,305 shares of the company’s stock after selling 3,983 shares during the period. Landscape Capital Management L.L.C.’s holdings in Axsome Therapeutics were worth $2,795,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Entropy Technologies LP acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at about $1,496,000. Barclays PLC increased its stake in shares of Axsome Therapeutics by 6.6% during the 4th quarter. Barclays PLC now owns 76,853 shares of the company’s stock worth $14,036,000 after purchasing an additional 4,786 shares during the last quarter. FORA Capital LLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth about $1,044,000. The Manufacturers Life Insurance Company increased its stake in shares of Axsome Therapeutics by 0.9% during the 4th quarter. The Manufacturers Life Insurance Company now owns 133,884 shares of the company’s stock worth $23,659,000 after purchasing an additional 1,167 shares during the last quarter. Finally, Bridgewater Associates LP acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth about $8,665,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $255.17 on Monday. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $257.92. The stock’s 50 day moving average is $210.94 and its 200-day moving average is $182.16. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The company has a market capitalization of $13.13 billion, a price-to-earnings ratio of -68.41 and a beta of 0.61.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The firm had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. The firm’s revenue for the quarter was up 57.4% compared to the same quarter last year. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.27 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Wolfe Research assumed coverage on shares of Axsome Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $230.00 price objective on the stock. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Monday, April 20th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price target on shares of Axsome Therapeutics in a research report on Thursday. Finally, Piper Sandler reissued an “overweight” rating and set a $258.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $256.79.

Insider Buying and Selling

In other news, CEO Herriot Tabuteau sold 49,670 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $241.01, for a total value of $11,970,966.70. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,742,261.29. This represents a 87.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Maizel sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the transaction, the insider directly owned 7,500 shares in the company, valued at $1,368,150. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 113,686 shares of company stock valued at $26,666,006 in the last ninety days. 20.60% of the stock is currently owned by company insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.